Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study

Autor: C.A. Uyl-de Groot, Z. Erjavec, E. (Vera) J. M. Mattijssen, Gerard Vreugdenhil, Kim M. Holtzer-Goor, Eduardus F. M. Posthuma, Simon Daenen, Peter C. Huijgens, P. W. Wijermans, W. G. Peters, H. Visser, M. R. Schaafsma, P. Joosten, S. Wittebol, M. H. J. Van Oers, K. G. van der Hem

Publikováno v: Quality of Life Research, 24(12), 2895-2906. Springer Netherlands
Quality of Life Research, 24(12), 2895-2906. SPRINGER
Holtzer-Goor, K M, Schaafsma, M R, Joosten, P, Posthuma, E F M, Wittebol, S, Huijgens, P C, Mattijssen, E J M, Vreugdenhil, G, Visser, H, Peters, W G, Erjavec, Z, Wijermans, P W, Daenen, S M G J, van der Hem, K G, van Oers, M H J & Uyl-de Groot, C A 2015, ' Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study ', Quality of Life Research, vol. 24, no. 12, pp. 2895-2906 . https://doi.org/10.1007/s11136-015-1039-y
Quality of Life Research, 24(12), 2895-2906. Springer, Cham
Quality of Life Research
Quality of life research, 24(12), 2895-2906. Springer Netherlands

Purpose To describe the health-related quality of life (HRQoL) of an unselected population of patients with chronic lymphocytic leukaemia (CLL) including untreated patients. Methods HRQoL was measured by the EORTC QLQ-C30 including the CLL16 module,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7058cbb1613db4d1a60c05ddf2daf4
https://doi.org/10.1007/s11136-015-1039-y

Real-world costs of chronic lymphocytic leukaemia in the Netherlands

Autor: Eduardus F. M. Posthuma, Z. Erjavec, Peter C. Huijgens, C Uyl de Groot, P. W. Wijermans, M. H. J. Van Oers, W. G. Peters, C. A M Bouwmans-Frijters, H. Visser, Simon Daenen, Kim M. Holtzer-Goor, S. Wittebol, E. (Vera) J. M. Mattijssen, Gerard Vreugdenhil, M. R. Schaafsma, P. Joosten, O. de Weerdt, K. G. van der Hem

Publikováno v: Leukemia Research, 38(1), 84-90. Elsevier Limited
Leukemia Research, 38(1), 84-90
Leukemia Research, 38(1), 84-90. PERGAMON-ELSEVIER SCIENCE LTD
Leukemia Research, 38, 84-90. Elsevier Ltd.
Leukemia research, 38(1), 84-90. Elsevier Limited
Holtzer-Goor, K M, Bouwmans-Frijters, C A M, Schaafsma, M R, de Weerdtc, O, Joosten, P, Posthuma, E F M, Wittebol, S, Huijgens, P C, Matthssen, E J M, Vreugdenhil, G, Visser, H, Peters, W G, Erjavec, Z, Wijermans, P W, Daenen, S M G J, van der Hem, K G, van Oers, M H J & Uyl-de Groot, C A 2014, ' Real-world costs of chronic lymphocytic leukaemia in the Netherlands ', Leukemia Research, vol. 38, no. 1, pp. 84-90 . https://doi.org/10.1016/j.leukres.2013.10.029

We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99ee7422143f41d5802dd07fb4984c6d
https://cris.maastrichtuniversity.nl/en/publications/2f0d9be9-f08e-4189-ac88-7a4f2fe7266b

High-dose melphalan with re-infusion of unprocessed, G-CFS-primed whole blood is effective and non-toxic therapy in multiple myeloma

Autor: A. R. Jonkhoff, A.H. Westra, Peter C. Huijgens, M. C. J. C. Legdeur, Gerrit Jan Schuurhuis, K. G. Van Der Hem, A. Boot-Bakker, Gert J. Ossenkoppele, Angelika M. Dräger

Publikováno v: European Journal of Cancer. 32:2058-2063

In order to shorten the pancytopenic period following high-dose melphalan 140 mg m us2 (HDM) treatment of multiple myeloma patients, we studied the effects of re-infusing granulocyte colony stimulating factor (G-CSF) [Filgrastim, Neupogen®]-primed u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fd851b0b691753bcb16bfe5a60ed1d9
https://doi.org/10.1016/s0959-8049(96)00267-5

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors

Autor: J.W. van Oostveen, S.F.T. Thijsen, A.P. Theijsmeijer, K G van der Hem, Gert J. Ossenkoppele, Joan H. Odding, Gerrit-Jan Schuurhuis, Angelika M. Dräger

Publikováno v: British Journal of Cancer
Thijsen, S F T, Schuurhuis, G J, van Oostveen, J W, Theijsmeijer, A P, van der Hem, K G, Odding, J H, Draeger, A M & Ossenkoppele, G J 1999, ' Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors ', British Journal of Cancer, vol. 79, pp. 1406-1412 . https://doi.org/10.1038/sj.bjc.6690225
British Journal of Cancer, 79, 1406-1412. Nature Publishing Group

Bryostatin-1 belongs to the family of macrocyclic lactones isolated from the marine bryozoan Bugula neritina and is a potent activator of protein kinase C (PKC). Bryostatin has been demonstrated to possess both in vivo and in vitro anti-leukaemic pot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82305a6e5f696b887746eb6f8f5a7090
https://pubmed.ncbi.nlm.nih.gov/10188883

Late relapse of testicular cancer. A case report and a review of the literature

Autor: K G, van der Hem, C J, van Groeningen, H M, Pinedo

Publikováno v: The Netherlands journal of medicine. 39(5-6)

A case of disseminated testicular cancer relapsing after 6 and 8 yr is reported, and the literature on late relapses is reviewed. About 4% of potentially cured testicular cancer patients do relapse after two or more years. Early detection is importan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::851193891109198524b15b8c4aa68844
https://pubmed.ncbi.nlm.nih.gov/1803248